Anika Therapeutics (ANIK) – Analysts’ Recent Ratings Changes

Share on StockTwits

Anika Therapeutics (NASDAQ: ANIK) has recently received a number of price target changes and ratings updates:

  • 3/5/2019 – Anika Therapeutics was given a new $35.00 price target on by analysts at Sidoti. They now have a “hold” rating on the stock.
  • 3/1/2019 – Anika Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 2/28/2019 – Anika Therapeutics had its “buy” rating reaffirmed by analysts at Singular Research.
  • 2/26/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 2/23/2019 – Anika Therapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 2/22/2019 – Anika Therapeutics had its price target lowered by analysts at Barrington Research to $44.00. They now have an “outperform” rating on the stock.
  • 2/22/2019 – Anika Therapeutics was downgraded by analysts at Sidoti from a “buy” rating to a “neutral” rating. They now have a $41.00 price target on the stock, down previously from $56.00.
  • 2/22/2019 – Anika Therapeutics was downgraded by analysts at First Analysis from an “outperform” rating to a “neutral” rating. They now have a $37.00 price target on the stock, down previously from $41.00.
  • 2/22/2019 – Anika Therapeutics was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 2/20/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 2/20/2019 – Anika Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 2/18/2019 – Anika Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $44.00 price target on the stock. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 1/29/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 1/25/2019 – Anika Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/25/2019 – Anika Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $41.00 price target on the stock. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 1/23/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 1/16/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 1/14/2019 – Anika Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $38.00 price target on the stock. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 1/11/2019 – Anika Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Shares of ANIK stock opened at $31.14 on Friday. Anika Therapeutics Inc has a 52-week low of $28.54 and a 52-week high of $54.88. The stock has a market capitalization of $482.32 million, a price-to-earnings ratio of 16.92, a PEG ratio of 2.12 and a beta of 1.56.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Thursday, February 21st. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.22. Anika Therapeutics had a net margin of 17.74% and a return on equity of 10.63%. The business had revenue of $27.00 million during the quarter, compared to the consensus estimate of $26.22 million. During the same period in the prior year, the firm posted $0.53 EPS. The firm’s quarterly revenue was down 8.2% compared to the same quarter last year. On average, equities analysts predict that Anika Therapeutics Inc will post 1.22 earnings per share for the current fiscal year.

In related news, CEO Joseph G. Darling bought 1,000 shares of the company’s stock in a transaction on Thursday, February 28th. The shares were purchased at an average cost of $33.20 per share, for a total transaction of $33,200.00. Following the completion of the purchase, the chief executive officer now directly owns 22,436 shares in the company, valued at $744,875.20. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Raymond J. Land sold 4,000 shares of the business’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $33.06, for a total transaction of $132,240.00. Following the completion of the transaction, the director now owns 18,992 shares in the company, valued at $627,875.52. The disclosure for this sale can be found here. Corporate insiders own 8.08% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Financial Gravity Companies Inc. purchased a new position in Anika Therapeutics in the fourth quarter valued at about $52,000. Massmutual Trust Co. FSB ADV purchased a new position in Anika Therapeutics in the fourth quarter valued at about $76,000. Municipal Employees Retirement System of Michigan purchased a new position in Anika Therapeutics in the fourth quarter valued at about $140,000. Metropolitan Life Insurance Co. NY boosted its stake in Anika Therapeutics by 382.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,141 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 4,075 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund purchased a new position in Anika Therapeutics in the fourth quarter valued at about $182,000. Hedge funds and other institutional investors own 90.21% of the company’s stock.

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Recommended Story: How to Invest in Growth Stocks

Receive News & Ratings for Anika Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply